Evolus, Inc. (NASDAQ:EOLS) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET
Company Participants
David Moatazedi - President, CEO & Director
Nareg Sagherian - Head of Global Investor Relations & Corporate Communications
Rui Avelar - Chief Medical Officer and Head of Research & Development
Conference Call Participants
Annabel Eva Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division
Douglas Dylan Tsao - H.C. Wainwright & Co, LLC, Research Division
Marc Harold Goodman - Leerink Partners LLC, Research Division
Navann Ty Dietschi - BNP Paribas Exane, Research Division
Sam Shimon Eiber - BTIG, LLC, Research Division
Serge D. Belanger - Needham & Company, LLC, Research Division
Uy Sieng Ear - Mizuho Securities USA LLC, Research Division
Operator
Good afternoon, everyone, and thank you for standing by. Welcome to Evolus' Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded and webcast live. [Operator Instructions] I would now like to turn the conference over to Nareg Sagherian, Vice President and Head of Global Investor Relations and Corporate Communications. Please go ahead.
Nareg Sagherian
Thank you, operator, and welcome to everyone joining us on today's call to review Evolus' second-quarter financial results. Our second-quarter press release is now on our website at evolus.com. With me today are David Moatazedi, President and Chief Executive Officer; and Rui Avelar, Chief Medical Officer and Head of R&D.
Today's call will include forward-looking statements. Actual results may differ materially due to risks and uncertainties outlined in our earnings press release and SEC filings. These forward-looking statements are based on current assumptions, and we undertake no obligation to update them. Additionally, we will discuss certain non-GAAP financial measures. These measures should be considered in addition to and not as a substitute for our GAAP results.
A reconciliation of GAAP to non-GAAP
- Read more current EOLS analysis and news
- View all earnings call transcripts